The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019-2023 update of the patent literature.

Aldose reductase (AKR1B1, EC: 1.1.1.21) is a recognized target for the treatment of long-term diabetic complications, since its activation in hyperglycemia and its role in the polyol pathway. In particular, the tissue-specificity of AKR1B1 expression makes the design of the traditional aldose reductase inhibitors (ARIs), and the more recent aldose reductase differential inhibitors (ARDIs), exploitable strategies to treat pathologies resulting from diabetic conditions.